EnteroBiotix, a leading clinical stage microbiome therapeutics company headquartered in Aberdeen, Scotland, has closed an oversubscribed seed extension investment and is set for international expansion following the opening of a new office in Boston, US.

The pre-series A round was led by Scottish angel firm Equity Gap and supported by existing investors the Scottish Investment Bank (the investment arm of Scottish Enterprise), the University of Aberdeen and the Bank Workers Charity. The company welcomed new investment from Barwell Plc, Gabriel, Syndicate Room, Fund Twenty8, NCIMB Limited and SIS Ventures. The new office in Cambridge, Massachusetts is supporting EnteroBiotix’s operations and business development activities in the US.

EnteroBiotix has also launched a strategic collaboration with the University of Glasgow to support translational research focused on identifying and evaluating precision antimicrobials that the company will combine with its whole ecosystem therapeutics to create an entirely novel medicinal product. The collaboration is supported by the Medical Research Council (MRC) Confidence in Concept (CiC) scheme.

The company currently has   pre-screened products available for use in Faecal Microbiota Transplantation (FMT) through our compassionate use programme. These products can be distributed to clinicians to use in FMT on named patient basis produced under a license from the Medicines and Healthcare Products Regulatory Agency (MHRA).

EnteroBiotix has developed a “functional platform” that is meant to use data generated from its current product treatments to isolate active ingredients and develop them as next generation therapies.